Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?
Open accessAbstract
While adult clinical trials of coronavirus disease 2019 (COVID-19) vaccines have moved quickly into phase 3 clinical trials, clinical trials have not started in children in the United States. The direct COVID-19 impact upon children is greater than that observed for a number of other pathogens for which we now have effective pediatric vaccines. Additionally, the role of children in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission has clearly been underappreciated. Carefully conducted phase 2 clinical trials can adequately address potential COVID-19 vaccine safety concerns. Delaying phase 2 vaccine clinical trials in children will delay our recovery from COVID-19 and unnecessarily prolong its impact upon children’s education, health, and emotional well-being, and equitable access to opportunities for development and social success. Given the potential direct and indirect benefits of pediatric vaccination, implementation of phase 2 clinical trials for COVID-19 vaccines should begin now.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Indirect benefits of vaccination include the likelihood of reduced transmission in the home and school settings, including transmission affecting vulnerable persons, and safer in-person learning.
“Indirect benefits include the likelihood of reduced transmission in the home and in school settings, including transmission affecting vulnerable persons, and safer in-person learning.26-29”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [26]
Without effective Covid-19 vaccines for this age group, children could potentially become ongoing reservoirs of infection and sources of newly emerging variants.
“Without effective Covid-19 vaccines for this age group, children could potentially become ongoing reservoirs of infection and sources of newly emerging variants.26,30”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · see citing works
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 6× · see citing works
“Data are now available from early phase adult clinical trials [2-6].”
BackgroundMethodInfluentialSelf-citationMultisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021680 · Cited by 2,660 · see citing works
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works
Whitney, C. G., Farley, M. M., Hadler, J. L., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A. L., Cieslak, P. R., Pilishvili, T., Jackson, D. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022823 · Cited by 2,230 · see citing works
Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S., Zhang, T., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30287-5 · Cited by 1,960 · see citing works
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works
Self-citationZheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X., et al. (2020) · BMJ · doi:10.1136/bmj.m1443 · Cited by 1,439 · see citing works
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156 · see citing works
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · see citing works
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works
Intussusception among Infants Given an Oral Rotavirus Vaccine
Murphy, T. V., Gargiullo, P. M., Massoudi, M. S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440804 · Cited by 978 · see citing works
The Japanese Experience with Vaccinating Schoolchildren against Influenza
Reichert, T. A., Sugaya, N., Fedson, D. S., Glezen, W. P., Simonsen, L., & Tashiro, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441204 · Cited by 860 · see citing works
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works
Rapid COVID-19 vaccine development
Graham, B. S. (2020) · Science · doi:10.1126/science.abb8923 · Cited by 771 · see citing works
Moore, M. R., Link‐Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., Petit, S., Zansky, S. M., Harrison, L. H., Reingold, A. L., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71081-3 · Cited by 732 · see citing works
Parashar, U. D., Alexander, J. P., & Glass, R. I. (2006) · PsycEXTRA Dataset · doi:10.1037/e531952006-001 · Cited by 675 · see citing works
Tomczyk, S. M., Bennett, N. M., Stoecker, C., Gierke, R., Moore, M. R., Whitney, C. G., Hadler, S. C., & Pilishvili, T. (2014) · PubMed Central · doi:10.15585/mmwr.mm6846a5 · Cited by 668 · see citing works
Roush, S. W. (2007) · JAMA · doi:10.1001/jama.298.18.2155 · Cited by 633 · see citing works
Surveillance for acute viral hepatitis--United States, 2006.
Wasley, A., Grytdal, S., & Gallagher, K. (2008) · PubMed · Cited by 543 · see citing works
Kim, L., WHITAKER, M. D., O’Halloran, A. C., Kambhampati, A. K., Chai, S. J., Reingold, A. L., Armistead, I., Kawasaki, B., Meek, J. I., Yousey-Hindes, K. M., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e3 · Cited by 513 · see citing works
Self-citationContact Tracing during Coronavirus Disease Outbreak, South Korea, 2020
Park, Y.-J., Choe, Y. J., Park, O., Park, S. Y., Kim, Y., Kim, J., Kweon, S., Woo, Y., Gwack, J., Kim, S. S., et al. (2020) · Emerging infectious diseases · doi:10.3201/eid2610.201315 · Cited by 499 · see citing works
Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US
Auger, K. A., Shah, S. S., Richardson, T., Hartley, D., Hall, M., Warniment, A., Timmons, K. M., Bosse, D., Ferris, S. A., Brady, P. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.14348 · Cited by 464 · see citing works
Surveillance for acute viral hepatitis--United States, 2005.
Wasley, A., Miller, J. T., & Finelli, L. (2007) · PubMed · Cited by 391 · see citing works
Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities
Loeb, M. B., Russell, M. L., Moss, L., Fonseca, K., Fox, J. D., Earn, D. J. D., Aoki, F. Y., Horsman, G. B., Caeseele, P. G. V., Chokani, K., et al. (2010) · JAMA · doi:10.1001/jama.2010.250 · Cited by 387 · see citing works
Yonker, L. M., Neilan, A. M., Bartsch, Y. C., Patel, A. B., Regan, J., Arya, P., Gootkind, E., Park, G. S. H., Hardcastle, M., John, A. S., et al. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.08.037 · Cited by 352 · see citing works
Heald-Sargent, T. A., Muller, W. J., Zheng, X., et al. (2020) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.3651 · Cited by 330 · see citing works
Varicella Mortality: Trends before Vaccine Licensure in the United States, 1970–1994
Meyer, P. A., Seward, J. F., Jumaan, A. O., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315714 · Cited by 280 · see citing works
Piedra, P. A., Gaglani, M., Kozinetz, C. A., Herschler, G. B., Riggs, M. W., Griffith, M., Fewlass, C., Watts, M., Hessel, C., Cordova, J. M., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.09.025 · Cited by 277 · see citing works
SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020
Szablewski, C. M., Chang, K. T., Brown, M. M., Chu, V. T., Yousaf, A. R., Anyalechi, N., Aryee, P. A., Kirking, H. L., Lumsden, M., Mayweather, E., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6931e1 · Cited by 214 · see citing works
Racial and/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children
Goyal, M. K., Simpson, J. N., Boyle, M. D., Badolato, G. M., Delaney, M., McCarter, R., & Cora‐Bramble, D. (2020) · PEDIATRICS · doi:10.1542/peds.2020-009951 · Cited by 206 · see citing works
Hospitalizations for varicella in the United States, 1988 to 1999
Galil, K., Brown, C. J., Lin, F., et al. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200210000-00009 · Cited by 203 · see citing works
Lopman, B. A., Curns, A. T., Yen, C., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir492 · Cited by 188 · see citing works
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children
France, E. K., Glanz, J., Xu, S., Hambidge, S., Yamasaki, K., Black, S. B., Marcy, M., Mullooly, J. P., Jackson, L. A., Nordin, J., et al. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1578 · Cited by 165 · see citing works
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)
Rostad, C. A., Chahroudi, A., Mantus, G. E., Lapp, S. A., Teherani, M., Macoy, L., Rostad, B. S., Milla, S. S., Tarquinio, K. M., Basu, R. K., et al. (2020) · PEDIATRICS · doi:10.1542/peds.2020-018242 · Cited by 149 · see citing works
Self-citationHospitalizations Associated With Rotavirus Gastroenteritis in the United States, 1993–2002
Charles, M. D., Holman, R. C., Curns, A. T., et al. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000215234.91997.21 · Cited by 141 · see citing works
Declining Hepatitis A Mortality in the United States during the Era of Hepatitis A Vaccination
Vogt, T. M., Wise, M. E., Bell, B. P., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/586899 · Cited by 89 · see citing works
Febrile Seizure Risk After Vaccination in Children 6 to 23 Months
Duffy, J., Weintraub, E., Hambidge, S. J., et al. (2016) · PEDIATRICS · doi:10.1542/peds.2016-0320 · Cited by 77 · see citing works
Protecting the Community Through Child Vaccination
Anderson, E. J., Daugherty, M., Pickering, L. K., Orenstein, W. A., & Yogev, R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy142 · Cited by 77 · see citing works
Self-citationThe Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Children
Kao, C. M., Orenstein, W. A., & Anderson, E. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa712 · Cited by 56 · see citing works
Self-citationA SARS-CoV-2 mRNA Vaccine — Preliminary Report
Schaefer, J. R., Sharkova, Y., & Nickolaus, T. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2026616 · Cited by 40 · see citing works
Esposito, D. H., Holman, R. C., Haberling, D. L., Tate, J. E., Podewils, L. J., Glass, R. I., & Parashar, U. D. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182254d19 · Cited by 36 · see citing works
Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration
Tau, N., Yahav, D., & Shepshelovich, D. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2726 · Cited by 13 · see citing works
Edwards, K. M., & Orenstein, W. A. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.06.048 · Cited by 7 · see citing works
Rotavirus-coded Deaths in Children, United States, 1999–2007
Desai, R. J., Esposito, D., Lees, C., et al. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318220fe20 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [39]Keech C, Albert G, Reed P, et al. First-in-human trial of a SARS CoV 2 recombinant spike protein nanoparticle vaccine. medRxiv 2020; doi: 2020.08.05.20168435. PMC7494251 32877576
- [48]Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395: 1845– 54. 32450106 PMC7255193
Cited by
Sorted by citations
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116298 · Cited by 593 · see citing works
Self-citationVaccinating Children against Covid-19 — The Lessons of Measles
Klass, P., & Ratner, A. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2034765 · Cited by 66 · see citing works
- Authors
- Anderson, E. J., Campbell, J. D., Creech, C. B., Frenck, R., Kamidani, S., Munoz, F. M., Nachman, S., & Spearman, P.
- Affiliations
- Emory University (US)
- University of Maryland, Baltimore (US)
- Vanderbilt University (US)
- Cincinnati Children's Hospital Medical Center (US)
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
- State University of New York (US)
- Corresponding author
- Anderson, Evan J
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-09-18
- Volume
- 73
- Issue
- 2
- Pages
- 336-340
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC7543330
- OpenAlex
- W3087530397
- Cited by
- 89
- References
- 48
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 7 · 2023: 13 · 2022: 27 · 2021: 32 · 2020: 6
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccines, SARS-CoV-2, vaccine safety, vaccine development timeline
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adult, Child, Humans, Vaccination, Viral Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
